Keep Me Logged In
Immunotherapy biotech company NantKwest shares opened at $37 in their trading debut, 48% above their IPO price. Patrick Soon-Shiong ,NantKwest CEO, discusses the company and success toward fighting cancer with "natural killers"
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2019 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by